John M Mariadason
Overview
Explore the profile of John M Mariadason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
4333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Togel L, Nightingale R, Wu R, Chueh A, Al-Obaidi S, Luk I, et al.
Sci Rep
. 2023 Feb;
13(1):2422.
PMID: 36765160
No abstract available.
12.
Augustine T, John P, Friedman T, Jiffry J, Guzik H, Mannan R, et al.
Front Oncol
. 2022 Nov;
12:1018767.
PMID: 36387154
The majority of colorectal cancers (CRCs) are microsatellite stable (MSS) and resistant to immunotherapy. The current study explores the possibility of using oncolytic reovirus to sensitize MSS CRC to immune...
13.
Jenkins L, Luk I, Fairlie W, Lee E, Palmieri M, Schoffer K, et al.
Mol Cancer Ther
. 2022 Nov;
22(1):52-62.
PMID: 36343387
The EGFR/RAS/MEK/ERK signaling pathway (ERK/MAPK) is hyperactivated in most colorectal cancers. A current limitation of inhibitors of this pathway is that they primarily induce cytostatic effects in colorectal cancer cells....
14.
Luk I, Jenkins L, Schoffer K, Ng I, Tse J, Mouradov D, et al.
Cell Death Differ
. 2022 May;
29(11):2288-2302.
PMID: 35606410
Colorectal cancers (CRCs) often display histological features indicative of aberrant differentiation but the molecular underpinnings of this trait and whether it directly drives disease progression is unclear. Here, we identify...
15.
Weickhardt A, Lau D, Hodgson-Garms M, Lavis A, Jenkins L, Vukelic N, et al.
BMC Cancer
. 2022 May;
22(1):478.
PMID: 35501832
Background: Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are...
16.
Chionh F, Gebski V, Al-Obaidi S, Mooi J, Bruhn M, Lee C, et al.
Sci Rep
. 2022 Jan;
12(1):1238.
PMID: 35075138
The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C)....
17.
Reehorst C, Nightingale R, Luk I, Jenkins L, Koentgen F, Williams D, et al.
Development
. 2021 Jun;
148(12).
PMID: 34180969
Ets homologous factor (EHF) is a member of the epithelial-specific Ets (ESE) family of transcription factors. To investigate its role in development and epithelial homeostasis, we generated a series of...
18.
Arulananda S, OBrien M, Evangelista M, Harris T, Steinohrt N, Jenkins L, et al.
Cell Death Discov
. 2021 Jun;
7(1):146.
PMID: 34131107
No abstract available.
19.
Arulananda S, OBrien M, Evangelista M, Jenkins L, Poh A, Walkiewicz M, et al.
Cell Death Discov
. 2021 May;
7(1):122.
PMID: 34050131
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell...
20.
Bazzocco S, Dopeso H, Martinez-Barriocanal A, Anguita E, Nieto R, Li J, et al.
Clin Epigenetics
. 2021 Apr;
13(1):88.
PMID: 33892786
Background: Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required...